206 related articles for article (PubMed ID: 35237300)
1. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis.
Liu T; Shen J; He Q; Xu S
Front Genet; 2022; 13():814291. PubMed ID: 35237300
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.
Xiao L; Shi XY; Li ZL; Li M; Zhang MM; Yan SJ; Wei ZL
J Gynecol Oncol; 2021 Sep; 32(5):e77. PubMed ID: 34132072
[TBL] [Abstract][Full Text] [Related]
4. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.
Zheng J; Guo J; Cao B; Zhou Y; Tong J
Cancer Cell Int; 2021 Jul; 21(1):363. PubMed ID: 34238292
[TBL] [Abstract][Full Text] [Related]
6. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
[TBL] [Abstract][Full Text] [Related]
7. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
8. Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.
Lei J; He ZY; Wang J; Hu M; Zhou P; Lian CL; Hua L; Wu SG; Zhou J
Cancer Med; 2021 Apr; 10(8):2924-2939. PubMed ID: 33742531
[TBL] [Abstract][Full Text] [Related]
9. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
Li H; Luo F; Jiang X; Zhang W; Xiang T; Pan Q; Cai L; Zhao J; Weng D; Li Y; Dai Y; Sun F; Yang C; Huang Y; Yang J; Tang Y; Han Y; He M; Zhang Y; Song L; Xia JC
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35277458
[TBL] [Abstract][Full Text] [Related]
10. Four Prognosis-Associated lncRNAs Serve as Biomarkers in Ovarian Cancer.
Zheng J; Guo J; Zhang H; Cao B; Xu G; Zhang Z; Tong J
Front Genet; 2021; 12():672674. PubMed ID: 34367239
[TBL] [Abstract][Full Text] [Related]
11. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
Guo J; Pan H
Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.
Yuan J; Li X; Wang F; Liu H; Guan W; Xu G
Exp Biol Med (Maywood); 2023 Dec; 248(23):2198-2209. PubMed ID: 38084732
[TBL] [Abstract][Full Text] [Related]
13. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis.
Zeng Q; Yi C; Lu J; Wang X; Chen K; Hong L
Cancer Med; 2023 Apr; 12(7):9024-9040. PubMed ID: 36708070
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of competitive endogenous RNAs networks reveals potential prognostic biomarkers associated with epithelial ovarian cancer.
Wu W; Gao C; Chen L; Zhang D; Guo S
Oncol Lett; 2021 Dec; 22(6):843. PubMed ID: 34777587
[TBL] [Abstract][Full Text] [Related]
15. A Potential Immune-Related Long Non-coding RNA Prognostic Signature for Ovarian Cancer.
Pan X; Bi F
Front Genet; 2021; 12():694009. PubMed ID: 34367253
[TBL] [Abstract][Full Text] [Related]
16. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
17. Excavating novel diagnostic and prognostic long non-coding RNAs (lncRNAs) for head and neck squamous cell carcinoma: an integrated bioinformatics analysis of competing endogenous RNAs (ceRNAs) and gene co-expression networks.
Yang L; Lu P; Yang X; Li K; Chen X; Qu S
Bioengineered; 2021 Dec; 12(2):12821-12838. PubMed ID: 34898376
[TBL] [Abstract][Full Text] [Related]
18. Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.
Su Y; Zhang T; Tang J; Zhang L; Fan S; Zhou J; Liang C
Front Oncol; 2021; 11():640150. PubMed ID: 33869028
[TBL] [Abstract][Full Text] [Related]
19. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
Front Immunol; 2021; 12():719175. PubMed ID: 34603293
[TBL] [Abstract][Full Text] [Related]
20. CTD-2020K17.1, a Novel Long Non-Coding RNA, Promotes Migration, Invasion, and Proliferation of Serous Ovarian Cancer Cells In Vitro.
Zhu L; Guo Q; Lu X; Zhao J; Shi J; Wang Z; Zhou X
Med Sci Monit; 2018 Mar; 24():1329-1339. PubMed ID: 29504606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
